58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment - Concepedia

Concepedia

Publication | Closed Access

58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment

27

Citations

0

References

2022

Year

Frederik Marmé, Claus Hanusch, Jenny Furlanetto, Patrick G. Morris, T. Link, Carsten Denkert, Peter A. Fasching, Christian Jackisch, Silvia Antolín, Christine Solbach,

Annals of Oncology

No additional data available for this publication yet. Check back later!